We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01534494
Recruitment Status : Unknown
Verified February 2014 by Michael Bogenschutz, University of New Mexico.
Recruitment status was:  Active, not recruiting
First Posted : February 16, 2012
Last Update Posted : February 10, 2014
Heffter Research Institute
Information provided by (Responsible Party):
Michael Bogenschutz, University of New Mexico

Brief Summary:
This trial is an open-label pilot study (N = 10) designed to assess the effects of psilocybin in alcohol dependent participants, demonstrate the feasibility of the integrated behavioral/pharmacologic intervention, and provide preliminary outcome and safety data. Participants will receive psilocybin orally in two all-day administration sessions, conducted in a secure outpatient psychiatric setting, in a dose range that has been well-tolerated in recent studies. Psilocybin administration will occur in the context of a behavioral intervention including a total of 12 sessions over 12 weeks, incorporating Motivational Enhancement Therapy (MET (Miller, Zweben et al. 1992; Miller 1995), based on Motivational Interviewing (Miller and Rollnick 2002)) with booster sessions, as well as preparation before and debriefing after the psilocybin administration sessions. The MET will incorporate attention to spirituality as well as drinking behavior as a primary subject of change. Drinking outcomes and changes in several potential mediators of treatment effect, including motivation, self-efficacy, craving, depression, anxiety, and spiritual dimensions of the experience, will be measured during treatment and for 24 weeks after the end of treatment. The investigators hypothesize that drinking will decrease following the psilocybin sessions, and that increases in motivation, self-efficacy, and spirituality (primary contrast 12 weeks vs. baseline) will be observed among study participants.

Condition or disease Intervention/treatment Phase
Alcohol Dependence Drug: Psilocybin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
Study Start Date : January 2012
Actual Primary Completion Date : September 2013
Estimated Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: psilocybin Drug: Psilocybin
two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.

Primary Outcome Measures :
  1. change in percent heavy drinking days [ Time Frame: weeks 5-12 post initiation of treatment vs. 12 weeks prior to treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and females age 25-65 with SCID diagnosis of alcohol dependence;
  2. Concerned about their drinking, but not planning to pursue any other form of treatment at present (12-step meetings are not considered treatment);
  3. Able to provide voluntary informed consent;
  4. Having at least 2 heavy drinking days in the past 30 days;
  5. Willing to commit to the goal of abstinence at least from the time of the first psilocybin administration session until the end of treatment.
  6. At least 24 hours abstinence from alcohol at the time of the psilocybin administration sessions;
  7. If female of childbearing potential, willing to use approved form of contraception from screening until after the psilocybin administration sessions;
  8. Having a family member or friend who can pick them up and stay with them overnight after the psilocybin administration sessions; and
  9. Able to provide adequate locator information.

Exclusion Criteria:

  1. Exclusionary medical conditions (e.g., seizure disorder, significantly impaired liver function, coronary artery disease, uncontrolled hypertension, history of cerebrovascular accident, severe obesity (BMI greater than or equal to 35);
  2. Exclusionary psychiatric conditions (schizophrenia, schizoaffective disorder, bipolar disorder, current major depression, current post-traumatic stress disorder, current suicidality);
  3. A family history of schizophrenia, schizoaffective disorder, bipolar disorder, or suicide (first or second degree relatives);
  4. Lifetime history of hallucinogen use on more than 10 occasions, or any use in the past 30 days;
  5. Cocaine, psychostimulant, or opioid dependence (past 12 months) or current (past 30 days) use;
  6. A history of medically significant suicide attempt or violent crime;
  7. Significant alcohol withdrawal (CIWA-Ar score greater than 7);
  8. Exclusionary laboratory abnormalities (any liver function test (LFT) greater than 5 times normal, ECG evidence of ischemia, serious abnormalities of complete blood count or chemistries);
  9. Active legal problems with the potential to result in incarceration;
  10. Pregnancy or lactation;
  11. The need to take excluded medication (e.g., antidepressants, antipsychotics, psychostimulants, pharmacologic treatments for addictions).
  12. High risk of adverse emotional reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, serious current stressors, lack of meaningful social support).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01534494

Layout table for location information
United States, New Mexico
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Heffter Research Institute
Layout table for investigator information
Principal Investigator: Michael P Bogenschutz, M.D. University of New Mexico
Layout table for additonal information
Responsible Party: Michael Bogenschutz, Professor of Psychiatry, University of New Mexico
ClinicalTrials.gov Identifier: NCT01534494    
Other Study ID Numbers: Heffter-UNM-HSC-15671
First Posted: February 16, 2012    Key Record Dates
Last Update Posted: February 10, 2014
Last Verified: February 2014
Keywords provided by Michael Bogenschutz, University of New Mexico:
alcohol dependence
clinical trial
motivational enhancement therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Physiological Effects of Drugs
Psychotropic Drugs